BELLUS Health Inc. (BLU) PT Raised to $18 at BTIG; 'Best-case Scenario Reached'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
December 13, 2021 7:00 AM ESTPrimary efficacy endpoint statistically significant with 34% placebo-adjusted reduction in 24-hour cough frequency observed at 50 mg and 200 mg BID doses (p 0.005)
BLU-5937 was well-tolerated with a low rate of taste-related adverse events (6.5%); treatment emergent adverse event profile comparable to placebo
Company also provides an update on its P2X3 pipeline and BLU-5937 Phase 2a trial for the treatment of chronic pruritus
Company to host conference call and webcast at 8:00 a.m. ET
LAVAL, Quebec--(BUSINESS WIRE)-- BELLUS Health Inc. (Nasdaq:BLU; TSX:... More
